Imatinib inhibits SARS-CoV-2 infection by an off-target-mechanism

Romano Strobelt1, Julia Adler1, Nir Paran2, Yfat Yahalom-Ronen2, Sharon Melamed2, Boaz Politi2, Ziv Shulman3, Dominik Schmiedel3,4 & Yosef Shaul1

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causal agent of the COVID-19 pandemic. More than 274 million individuals have suffered from COVID-19 and over five million people have died from this disease so far. Therefore, there is an urgent need for therapeutic drugs. Repurposing FDA approved drugs should be favored since evaluation of safety and efficacy of de-novo drug design are both costly and time consuming. We report that imatinib, an Abl tyrosine kinase inhibitor, robustly decreases SARS-CoV-2 infection and uncover a mechanism of action. We show that imatinib inhibits the infection of SARS-CoV-2 and its surrogate lentivector pseudotype. In latter, imatinib inhibited both routes of viral entry, endocytosis and membrane-fusion. We utilized a system to quantify in real-time cell–cell membrane fusion mediated by the SARS-CoV-2 surface protein, Spike, and its receptor, hACE2, to demonstrate that imatinib inhibits this process in an Abl1 and Abl2 independent manner. Furthermore, cellular thermal shift assay revealed a direct imatinib-Spike interaction that affects Spike susceptibility to trypsin digest. Collectively, our data suggest that imatinib inhibits Spike mediated viral entry by an off-target mechanism. These findings mark imatinib as a promising therapeutic drug in inhibiting the early steps of SARS-CoV-2 infection.

In December 2019, a new respiratory disease appeared in Wuhan, China, and became a global pandemic within a few months1–3. The identified agent, a coronavirus, showed substantial similarity to a previous virus that lead to an outbreak in 2003 with the severe acute respiratory syndrome coronavirus (SARS-CoV-1), and were therefore named SARS-CoV-2. The respective disease was named coronavirus disease 2019 (COVID-19) and has a mortality of around 2%, causing more than 5.3 million global death so far5,6. Since available medical interventions directly against COVID-19 are lacking and the pandemic is still ongoing, it is crucial to identify possible drug targets for preventing severe outcomes of infected individuals. Already FDA-approved drugs should be herby in the main focus of researchers considering long-lasting clinical trials for developing new medical intervention.

SARS-CoV-2 is a member of the Coronaviridae family that includes some highly pathogenic strains like middle east respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV-17–9. Members of Coronaviridae infiltrate the respiratory tract, SARS-CoV-2 by using angiotensin converting enzyme 2 (hACE2) as the entry receptor and transmembrane serine protease 2 (TMPRSS2) for priming10,11. After binding of SARS-CoV-2 surface protein (Spike) to hACE2, the virion undergoes membrane fusion or receptor-mediated endocytosis dependant on the presence or absence of TMPRSS2, respectively9,12–14. An initial step within the infection cycle is the consecutive cleavage of Spike at two sites S1/S2 and S2’ (S2) by furin, trypsin, endosomal cathepsin L and/or membrane protease TMPRSS2. The cleavage exposes the fusogenic peptide, causing the conformational change of Spike and promoting the fusion of virus and host membrane7,10,11,15.

In tissue culture, the Abelson tyrosine-kinase inhibitor, imatinib, inhibits SARS-CoV-1 and MERS-CoV infection, however the underlying mechanisms remain elusive16–18. Recent studies suggest that this is the case for SARS-CoV-2, as well19–21. Imatinib is an FDA-approved drug currently used for treating chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). The therapeutic effect of imatinib in cancer derives mainly from inhibiting Abelson kinase 1 (Abl1) and Abelson-related gene protein (Abl2, also known as Arg)22–24. Both proteins are non-receptor tyrosine kinases with diverged cellular functions5,25.

It has been reported that imatinib blocks the early stages of SARS-CoV-1 and MERS infection by inhibiting fusion of the virions at the endosomal membrane18. Furthermore, based on the prevention of virus-induced
syncytia formation, it has been argued that imatinib and other Abl-kinase inhibitors inhibit cell–cell fusion. Although Abl2 depletion reduces SARS-CoV-2 infection, it is unclear whether Abl2 regulates both endocytic and cell membrane fusion. We report here that imatinib inhibits SARS-CoV-2 infection and Spike-mediated cell–cell membrane fusion in Abl-kinases knockout cells suggesting an imatinib off-target effect. Furthermore, we show that imatinib did not impair hACE2-Spike-interaction but rather stabilized Spike protein and changed its sensitivity to trypsin digestion, which suggests a direct interaction of imatinib with Spike.

**Results**

**Imatinib impedes early steps of SARS-CoV-2 infection.** To investigate whether imatinib inhibits SARS-CoV-2 infection, we pre-treated VeroE6 with increasing concentrations of imatinib 2 h prior to infection with SARS-CoV-2 at 0.01 MOI, followed by 24 h incubation. The infectious virions were quantified by viral titration. Results represent one of three biological replicates. (b) Imatinib treatment strongly reduced SARS-CoV-2-RNA-levels within the infected cells. VeroE6 cells were imatinib treated and 2 h later infected with SARS-CoV-2. At 24 h, cells were harvested for RNA extraction. The level of viral RNA was quantified by real-time PCR and normalized to β-Actin RNA level. Results represent three technical replicates. (c) Imatinib treatment before SARS-CoV-2 infection is more effective than after infection. VeroE6 cells were infected with SARS-CoV-2 at 0.01 MOI and 2 h later treated with imatinib for 48 h. Results represent four technical replicates. In panels (a) to (c) data were statistically evaluated with One-Way ANOVA and Dunnett posttest. The data are normalized for the imatinib toxic effects according to XTT results of Fig. S1. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.

**Imatinib inhibits SARS-CoV-2 pseudovirus infection.** Next, we generated lentivirus-based SARS-CoV-2 pseudoviruses and performed the experiments at biosafety level 2 conditions (BSL2). To this end, we truncated 19 amino acids from the C-terminus of the Spike protein in order to delete the ER localization signal and redirect it to the cell membrane. The constructed lenti-SARS-CoV-2-Spike-pseudovirus (lenti-Spike) expressed GFP upon transduction, and infection efficiency was quantified by determining the ratio between infected and non-infected cells. We show that imatinib inhibited lenti-Spike infection in a dose-dependent manner. Strong inhibition of lenti-Spike infection was obtained when imatinib was added either 2 h prior to infection, or mixed with lenti-Spike sample before transduction. Thus, we believe that optimal therapeutic application of imatinib would be obtained either at the first days of infection while virus is spreading within the body or as prophylactic use. Here too, a much lower level of inhibition was obtained when cells were treated 2 h after lenti-Spike infection.
affected by imatinib (Fig. 2c). Since no lenti-Spike replication is involved in these conditions, we concluded that imatinib acted at the level of lenti-Spike specific cell attachment or entry steps. Furthermore, HEK293T-hACE2 cells pretreated with imatinib for 2 h but washed-out shortly before lenti-Spike addition were well transduced (Fig. S2c), suggesting that imatinib is required at the time of infection.

**Imatinib inhibits both endocytosis and membrane fusion infection pathways.** It was previously reported that the presence or absence of TMPRSS2 determines the SARS-CoV-2 entry route either via mem-
brane fusion or endocytosis, respectively\textsuperscript{1,11,14}. E64d, a cathepsin L inhibitor, significantly inhibits endosomal SARS-CoV-2 infection mainly in the absence of TMPRSS2 while camostat, a serine-protease-inhibitor, inhibits membrane-fusion-mediated infection in the TMPRSS2 positive cells\textsuperscript{10}.

HEK293T\textsuperscript{7} do not express TMPRSS2 and cells ectopically expressing TMPRSS2 were more susceptible to infection with both SARS-CoV-2 and the related pseudovirions\textsuperscript{9}. We observed similar behavior with lentivirus infection. In the absence of TMPRSS2, lenti-Spike infection of HEK293T-hACE2 was robustly inhibited with both E64d and imatinib but not camostat (Fig. 2d). However, in the TMPRSS2 positive cells, the level of inhibition by imatinib was significantly higher over that of E64d (Fig. 2e). While E64d and camostat effects are dependent on the presence or absence of TMPRSS2, respectively, imatinib was active in both cases, indicating that imatinib effectively inhibits both routes of infection; receptor-mediated-endocytosis and membrane fusion.

**Imatinib slows down Spike-mediated syncitia-formation.** Syncitia formation, obtained by cell-to-cell fusion, characterizes Coronavirusidae infection\textsuperscript{12,28}. It describes a cytopathic effect promoting virion-free cell-to-cell spread, tissue damage and cell death\textsuperscript{29}. Having demonstrated that imatinib inhibited the very early steps of infection, we next asked whether the inhibition is at the level of membrane fusion. To this end, we established a quantitative cell–cell membrane fusion assay. For visualizing and quantifying fusion events in real-time, we used a bimolecular fluorescence complementation (BiFC) approach. We transfected cells with either Spike and Fos-YFPc (C-terminal fragment of YFP) or hACE2 and Jun-YFPn (N-terminal fragment of YFP). Jun and Fos are nuclear transcription factors that heterodimerize in the nucleus. Cell nuclei become YFP positive only upon cell fusion and complementation of split-YFP via Jun-Fos heterodimerization (Fig. 3a, b)\textsuperscript{30,31}. Cells were treated with imatinib 2 h prior to their mixing and YFP positive cells were quantified at different time points. Interestingly, imatinib significantly inhibited fusion kinetics dose-dependently, whereas E64d was barely active (Fig. 3c). Since E64d drug targets the endosomal localized cathepsin L, it would explain why our assay of cell–cell fusion is E64d refractory\textsuperscript{14,15,32}.

Next, we ectopically expressed TMPRSS2 to establish the HEK293T-hACE2-TMPRSS2 cell line. Imatinib inhibited HEK293T-hACE2-TMPRSS2 cell fusion kinetics as well (Fig. 3d). As expected, under these conditions, camostat robustly inhibited cell–cell fusion, validated the role of TMPRSS2 at the level of cell membrane fusion\textsuperscript{14,15}. Imatinib slowed down Spike-mediated-fusion and the cytopathic syncitia formation in both TMPRSS2-negative and -positive cells. These results suggest that imatinib inhibited infection by diminishing the Spike-mediated fusion.

**Imatinib inhibits lenti-Spike infection in an Abl1 and Abl2 independent manner.** Next, we asked whether Abl1 or Abl2, the direct imatinib targets, are required for the early steps of pseudovirus infection. To this end, we created HEK293 Abl1 knockout (Abl1KO), Abl2KO and double Abl1/Abl2KO, two single clones of each (Figs. S3 and S4). We overexpressed hACE2 alone or together with TMPRSS2 in the KO cells and evaluated lenti-Spike infection and its susceptibility to imatinib. Differences at the level of transfection efficiency between Abl-KO-lines were evident, however, the normalized data revealed that imatinib inhibited lentivirus infection in all to the same level (Fig. 4a). This effect was also observed in the presence of TMPRSS2 (Fig. 4b).

Next, we monitored cell fusion rate in the established Abl-KO cell lines. A strong reduction at the level of cell–cell fusion was observed in imatinib-treated cells, in the presence and absence of TMPRSS2 (Figs. S5 and S6). These results suggest that imatinib inhibited lenti-Spike infection and Spike-mediated cell fusion in an Abl1 and Abl2 independent manner.

**Imatinib affects Spike conformation.** Since imatinib reduced the rate of Spike-mediated infection and fusion in Abl independent manner, we next asked whether imatinib blocks hACE2-Spike-interaction. We performed a cell–protein-interaction-assay to quantify hACE2-Spike-binding at the cellular level. Fluorophore alexa-488 labeled Spike (Spike-AF488) was incubated with HEK293T-hACE2 cells and were either imatinib or DMSO treated on ice for 30 min. The number of cells labeled with Spike-AF488 was determined at room temperature using flow cytometry. No reduction at the level of positive cells was evident in the imatinib-treated cells, but rather a slight increase, suggesting that imatinib did not inhibit hACE2-Spike-interaction (Fig. 5a).

A possible explanation for the extended localization of Spike after imatinib treatment could be either an increased Spike-hACE2 interaction or a reduced Spike cleavage rate. So, we employed the immunoprecipitation (IP) assay to quantify hACE2-Spike-interaction in the transfected cells. Flag-Spike IP was brought down hACE2-Myc and the reciprocal experiment Flag-Spike was brought down by hACE2-Myc IP (Fig. 5b), validating their strong physical interaction. Here too, the interaction was imatinib refractory.

Next, we asked whether imatinib affects the cleavage rate of Spike. The cleavage of S0 to S2 exposes Spike fusion peptide, a critical step in virion–cell membrane fusion\textsuperscript{14,15}. We isolated Flag-Spike from transfected cells and digested it in vitro with trypsin at different time points. We did not observe a change in the cleavage pattern, and the digestion of S0, the full-length Spike was only marginal protected by imatinib. The Spike cleavage product S2, however, was more trypsin resistant and accumulated in higher quantity in the presence of imatinib (Fig. 5c). These results suggest that imatinib influenced Spike conformation.

For validating imatinib-induced stabilization of Spike conformation, we used cellular thermal shift assay (CETSA)\textsuperscript{32,33}, which allows studies of protein–ligand interactions in a cellular context. With increasing temperature, proteins are denatured, aggregated and insolubilized. This assay measures protein insolubility with increasing temperature which can change upon protein–drug interaction. Remarkably, we found that in the presence of imatinib the different Spike fragments are more stable at higher temperatures (Figs. 3d and S7). These results further suggest that imatinib directly binds Spike and affects its conformation.
**Discussion**

In this study, we provide evidence for imatinib inhibiting Spike mediated membrane fusion by an off-target mechanism. Infection of both SARS-CoV-2 and a surrogate lenti-Spike were blocked by imatinib (Figs. 1a, 2b),
Stabilizes its conformation in high temperatures (Figs. 5d and S7), respectively. While computational studies predicted that imatinib reduces hACE2-Spike-interaction, we could not confirm this effect (Fig. 5a, b)39–42. Our experiments showed that indeed imatinib binds Spike and changes its susceptibility to trypsin digestion (Fig. 5c) and to the Spike21,39–42. We experimentally challenged the Spike binding prediction, both in a cell-free system and in S6) and found that the imatinib effect on these processes are both Abl1 and Abl2 refractory.

Figure 4. Lenti-Spike inhibiting effects of imatinib were Abelson-kinases independent. (a) Lenti-Spike inhibition by imatinib is Abelson-kinases independent in TMPRSS2-negative cells. HEK293-KO cells for each Abl1, Abl2 or both, were transfected with hACE2 2 days before infection. Lenti-Spike infection is reduced in the same level in all the tested cell lines when treated with 10 µM imatinib at the time of infection. Results represent means of two independent experiments with two biological replicates each. (b) Abelson-kinases are not responsible for lenti-Spike inhibition with imatinib in TMPRSS2-positive cells. The Abl-KO cell lines were transfected with TMPRSS2 and hACE2 2 days before lenti-Spike infection. Results represent means of two independent experiments with two biological replicates each and student-t-test was applied; *p ≤ 0.05; **p ≤ 0.01.

Imatinib is a widely used inhibitor of the non-receptor Abl1 and Abl2 tyrosine kinases. Given the fact that lenti-Spike is replication-incompetent, imatinib mode of action does not require viral replication. Further study revealed that imatinib inhibited membrane fusion mediated by Spike and hACE2 (Fig. 5c, d). In the absence of TMPRSS2, imatinib was as potent as the cathepsin L inhibitor (E64d) in blocking lenti-Spike infection (Fig. 2d), suggesting that imatinib inhibits infection in endosomal pathway. Interestingly, our results also show that imatinib is active in TMPRSS2 positive cells (Fig. 2e), where the lenti-Spike cell entry is mediated via virus-cell membrane fusion. This finding is further supported by quantifying cell–cell fusion. Under this experimental setting the infection’s endosomal route is eliminated and indeed the fusion is refractory to the cathepsin L inhibitor (Fig. 3c). However, in the presence of TMPRSS2, cell–cell fusion is blocked by TMPRSS2 inhibitor (camostat) and by imatinib (Fig. 3d). Since SARS-CoV-2 encompasses multi-organ tropism, it can infect various tissues, TMPRSS2-negative and -positive, as observed in severe COVID-19-cases35–37. The finding that imatinib inhibited both pathways of SARS-CoV-2 infection may point to imatinib’s superiority over other SARS-CoV-2 entry-inhibitors such as hydroxychloroquine (HCQ), E64d or camostat that are limited on their specificity to either endosomal or membrane fusion route of infection10,14,15,38.

Since imatinib is a relatively specific inhibitor of Abl1 and Abl2, the question is whether these tyrosine kinases participate in SARS-CoV-2 infection. In the context of SARS-CoV-1 and MERS, it has been reported that Abl2 knockdown reduces infection37. Since the employed cell lines are TMPRSS2 negative in the reported study, the involvement of Abl2 might likely be relevant to the endosomal route of infection37. The author’s conclusion that Abl-kinases participate in membrane-membrane fusion is based on quantification of virus-induced syncytia formation38. However, syncytia are formed upon Spike expression by the infected cells and therefore the observed reduction in the syncytia formation is the direct outcome of infection efficiency. Therefore, to investigate the role of Abl-kinases in membrane-membrane fusion more direct measurements are required. Here, we used protocols to selectively quantify infection via virus-membrane (Fig. 4b) and membrane-membrane fusion (Figs. S5 and S6) and found that the imatinib effect on these processes are both Abl1 and Abl2 refractory.

Computational studies predicted the direct binding of imatinib to hACE2 while others predicted its binding to the Spike21,39–42. We experimentally challenged the Spike binding prediction, both in a cell-free system and in cells and found that indeed imatinib binds Spike and changes its susceptibility to trypsin digestion (Fig. 5c) and stabilizes its conformation in high temperatures (Figs. 5d and S7), respectively. While computational studies predicted that imatinib reduces hACE2-Spike-interaction, we could not confirm this effect (Fig. 5a, b)39–42. Our findings demonstrate that imatinib binds Spike, introduces conformational changes and abrogates its processing rates. Given these findings and the finding that imatinib effects are Abl1 and -2 refractory, we concluded that imatinib is active by an off-target mechanism.

Interestingly, tyrosine-kinase-inhibitors show antiviral properties also against other viruses, including MERS, ebolavirus, coxsackievirus, hepatitis C virus (HCV), influenza and human immunodeficiency virus (HIV)43–47. Since these viruses do not share the same surface antigen, it is rather unlikely that imatinib has a similar off-target mechanism in these above-mentioned examples. In case of HIV, Abl-kinases influence wave2-signaling and in-turn hemifusion of virus and cell membrane43. In ebolavirus infection, Abl1 inhibits replication, but not entry47. Imatinib therefore can inhibit viral infection via both Abl kinases-dependent and -independent mechanisms.

Our results clearly demonstrate that imatinib is an effective SARS-CoV-2 entry-inhibitor. Therefore, imatinib therapeutic effects are optimally obtained upon its utilization at the prior or early stage of infection. But apart from Spike, additional imatinib-mediated mechanisms that impair SARS-CoV-2 infection may exist. For example,
Figure 5. Imatinib affected Spike conformation via direct binding. (a) Imatinib increased the localization of Spike on cell surface. Spike-AF488 was added to HEK293T-hACE2 with or without 20 µM imatinib and incubated for 30 min on ice following 5 min in RT. The number of cells labeled with Spike-AF488 was quantified using flow cytometry. The data were analyzed by student t-test; *p ≤ 0.05. (b) Imatinib did not change Spike-hACE2 interaction. HEK293T were transfected with hACE2-Myc or Spike-Flag each alone or together and extracts were subjected to immunoprecipitation using the indicated antibodies. The immunoprecipitated proteins were analyzed by SDS-PAGE and immunoblotting (WB) using the indicated antibodies. Result represents one of two experiments. (c) Imatinib decreased the enzymatic cleavage rate of Spike. Spike-Flag was overexpressed, purified, and treated with either DMSO or 20 µM imatinib for an hour. Trypsin was added to a final concentration of 200 ng/ml and incubation was stopped at different time points by mixing the samples with Laemmli-buffer and boiling for 5 min. SDS-PAGE and WB was performed and position of S0 (unprocessed) and S2 (processed) Spike are indicated. Blue numbers indicate band intensity ratio compared to lane 0 min. Result represents one of three separate experiments. (d) Imatinib bound Spike, analysis by CETSA. Intact cells overexpressing Spike-Flag were treated with 20 µM imatinib or DMSO for 3 h, then incubated under increasing temperature (°C) and extracted. The insoluble fractions were removed by centrifugation and the soluble fractions subjected to SDS-PAGE and WB using the indicated antibodies. Actin and proteasomal subunit Psmd1 served as controls. Band intensity was calculated based on the values obtained at 42 °C. The numbers of DMSO and imatinib treatment are shown in gray and blue, respectively. Result represents one of three biological replicates.
Yogalingam et al. showed that imatinib interferes with protein glycosylation possibly interfering with SARS-Cov-2 maturation since several viral proteins are known to be modified by carbohydrates. Furthermore, imatinib treatment for 24 h significantly reduces ACE2 expression in both cell culture and mice. These effects were especially observed inside the lungs and could theoretically lead to less SARS-CoV-2-cell-interaction and consequently reduced infection. Additionally, imatinib is known to suppress the immune system. Since most SARS-CoV-2 patients die from an immunological overreaction known as cytokine storm, imatinib immunosuppressive effect could improve disease outcome of severe COVID-19 patients. Therefore, immunosuppressants like dexamethasone are highly recommended for critically COVID-19 patients needing mechanical ventilation. An initial clinical trial revealed that COVID-19 patients treated with imatinib show reduced mortality and shorter period of mechanically ventilation treatment compared with placebo groups. Indeed, the world health organization (WHO) regards imatinib as a promising drug in treating COVID-19.

**Methods**

**Cell culture.** Human embryonic kidney cells over expressing SV40 large T-antigen (HEK293T, ATCC), HEK293T expressing human angiotensin converting enzyme 2 (HEK293T-hACE2) or both ACE2 and TMPRSS2 (HEK293T-hACE2-TMPRSS2) were cultured in Dulbecco’s modified eagle’s medium (DMEM, Gibco®) with 8% fetal bovine serum (FBS, Gibco®) and 100 units/ml penicillin and 100 µg/ml streptomycin (pen/strep; Biological Industries®). African green monkey kidney clone E6 cells (VeroE6, ATCC® CRL-1586) were grown in DMEM containing 10% FBS, MEM nonessential amino acids (NEAA), 2 µM L-glutamine, pen/strep and 12.5 Units/ml nystatin (P/S/N), all from Biological Industries®. All cells were cultured at 37 °C, 5% CO2 with 95% humidity. HEK293T-hACE2 cells were established by lentivector hACE2-4xMyc gene from pLent6-hACE2-4xMyc construct and additional selection with 15 µg/ml blasticidin. In order to create HEK293T-hACE2-TMPRSS2, HEK293T-hACE2 were transfected with the respective plasmids 36 h before experimental setting and treated with 1 µg/ml puromycin 18 h before treatment. HEK293-Abi-KO cells derived from HEK293 TAF ts cell line as previously described. KO was verified by Synthego ICE analysis for each clone (Figs. S3 and S4). For experiments, cells were non-enzymatically harvested with phosphate-passed saline (PBS) + 1 mM EGTA. Between regular passages, cells detached from culture plate using trypsin solution B (Biological Industries®).

**Preparation of SARS-CoV-2 stock and infection.** SARS-CoV-2 (GISAID accession EPI_ISL_406862) was kindly provided by Bundeswehr Institute of Microbiology, Munich, Germany. Virus stocks were propagated (four passages) and titrated on VeroE6. Handling and working with SARS-CoV-2 virus were conducted in a BSL3 facility in accordance with the biosafety guidelines of the Israel Institute for Biological Research.

VeroE6 cells were seeded in 24-well plates (2.5 × 10^5 cells/well). Next morning, SARS-CoV-2 stocks were diluted in infection medium (MEM containing 2% FBS with NEAA, glutamine, and P/S/N) and used to infect VeroE6 in duplicates (200 µl/well) at 0.01 MOI. Imatinib pre-treatment experiments were performed by adding imatinib at respective concentrations for 2 h prior to SARS-CoV-2 infection. Following infection, cells were incubated for 24 h in MEM medium containing 2% FBS with NEAA, 2 mM L-glutamine, P/S/N and sodium bicarbonate, culture media (supernatant) were collected from each well for viral titration, while cell pellets were harvested for RNA. Imatinib post-treatment experiments were performed by adding imatinib at 2 h post SARS-CoV-2 infection, and incubation for 48 h. At 48 h post infection, supernatant was collected from each well for viral titration.

**Viral titration.** For determination of viral titers of SARS-CoV-2 following pre- or post-infection imatinib treatment, VeroE6 were seeded in 12-well plates (5 × 10^4 cells/well). 24 h later, supernatants from each of the above-mentioned treatment conditions were serially diluted in infection medium and used to infect VeroE6. Plates were incubated for 1 h at 37 °C to allow viral adsorption. Then, 2 ml/well of overlay (MEM containing 2% FBS and 0.4% tragacanth, Merck®) was added and plates were incubated for 72 h. The media were then aspirated, and the cells were fixed and stained with 1 ml/well of crystal violet solution (Biological Industries®). The number of plaques in each well was determined, and SARS-CoV-2 titers were calculated.

**RNA extraction and analysis.** Cells were harvested and RNA isolated with TRI reagent (BioLab®) according to the manufacturer instructions. Reverse transcription was performed by using qScript cDNA synthesis kit (Quantabio) according to the manufacturer guideline. To measure viral SARS-CoV-2 RNA, we performed real-time PCR using extracted cDNA, PerfeCTa SYBR® Green FastMix® and primer pair fw-GCC TCT TCT CGT TCC and rv-AGC AGC ATC ACC GCC ATT G for SARS-CoV-2 and compared expression with housekeeping gene β-Actin and primer pair fw-ATC GTG CGT GAC ATT AAG GAG and rv-AGG AAG GAA GGC TGG AAG AG.

**Plasmids.** pCMV3-SARS-CoV-2-spike plasmid (pCMV3-Spike) is a gift from Ron Diskin lab. Via PCR we truncated 19AA from C-terminal part or added Flag-tag at C-terminal part and subcloned it back in the same plasmid backbone (pCMV3-Δ19Spike or pCMV3-SARS-Spike-Flag). For the construction of pLent6-hACE2-4xmyc we first cloned hACE2-4xmyc first into pENTR plasmid with restriction sites NcoI and KpnI. Afterwards we used restriction-free cloning method via Gateway® LR-clonase-II (Invitrogen) and the manufactural protocol. For pEFIREs-hACE2-4xMyc we used restriction sites Nhel and MluI and for pEFIREs-TMPRSS2-Flag Nhel and XbaI restriction sites. For cell-fusion-assay, pBiFC-VN173 (Addgene) was used to fuse Jun upstream to YFPn (Jun-YFPn), using HindIII and BglII restriction sites. pBiFC-CC155 (Addgene) was used to fuse Fos upstream to the YFPC (Fos-YFPC) using EcoRI and KpnI restriction sites.
Transfection. All transfections were conducted using the calcium-phosphate (CaPO₄) method, when cells reached 70–80% confluency. DNA mix was prepared containing 8 µg DNA and 1:10 of 2.5 M calcium chloride (CaCl₂) in water. Next, same amount of 2X HEPES buffered saline (HBSx2) was dropwise added while vortexing. Finally, the obtained total mix was incubated for one min and dropwise added to cells. The medium was replaced with fresh growth medium after 8 h.

Pseudovirus infection. In 6 cm plate, HEK293T were transfected with pCMV-Δ19Spike (1.5 µg), pGIPZ-tGFP (3.5 µg) and ΔR8.9 plasmids (3 µg). Medium was replaced with 3 ml growth medium after 8 h and cells were extracted 48 h later. The virus containing medium were filtered through 0.45 µm cellulose filter (Sartorius) and used to transduce cells. Medium was changed after 8 h and analyzed after additional 24 h. Before analyzing, cell nuclei were stained with Hoechst solution. For estimating transduction efficiency, ratio of Hoechst-stained nuclei and GFP infected cells was calculated using the ImageJ software (macro see supplement).

Cytotoxicity assay. VeroE6 or HEK293T-hACE2 cells were seeded 4000 or 8000 cells/well of 96-well plate. After 24 h growth medium was replaced with increasing concentration of Imatinib (Novartis) and washed away after 8 h. Two days later cell viability was measured using the XTT cell proliferation kit (Biological Industries). Cells were treated with camostat (Tocris) and E64d (Caymanchem) in reported doses. Immuno-precipitation (IP) and western blotting. Cells were harvested with cold PBS and centrifuged for 5 min at 3500 rpm at 4 °C. The obtained pellets were resuspended in RIPA-buffer containing protease inhibitor (APEXBio®). Then the cell lysates were centrifuged at 4 °C for 15 min, and the supernatant were mixed either with Laemmli buffer or for IP with Flag- or Myc- beads (Sigma) and incubated for 4 h at 4°C in rotator. Before mixing IP fractions with Laemmli buffer, washing steps and elution with either Flag or Myc peptide (Sigma) were performed. SDS-PAGE and immunoblotting were done using described protocol. EZ-ECL kit (Biological Industries) was used to enhance signal of horseradish peroxidase-conjugated secondary antibodies (Jackson Immuno Research Laboratories). Recording was done with ImageQuant LAS 4000 (GE Healthcare). The following primary antibodies were used in this study: mouse anti-Actin (Sigma), mouse anti-HA (Sigma), mouse anti-Flag (Sigma), mouse anti-Myc (9E10; Weizmann Institute, Rehovot, Israel) and mouse anti-PSMD1 (Antibodyverify®).

Cell-fusion-assay. Cells were transfected with either Spike and Fos-YFPc or hACE2 and Jun-YFPn and the control RFP-plasmid. After 1.5 days cells were non-enzymatically harvested and adjusted to a concentration of 1.0 x 10⁶ cells for 24-well-plate. Next, drugs were added to the cell suspension and incubated for 2 h with frequent gentle vortexing. Cells were divided in duplicates and mixed in 1:1 ratio and plated. Next, cells were transferred to IncuCyte system (Sartorius), and pictures were taken in brightfield, GFP and RFP-channel in half an hour interval. Calculation of YFP intensity were done with IncuCyte intern software.

Cell–protein-interaction-assay. Purified Spike binding fluorophore Alexa Fluor 488 (Spike-AF488) was added to HEK293T-hACE2 together with DMSO or 20 µM imatinib and low speed centrifuged for 7 min at 4°C. Next, cells were incubated for 30 min on ice and gently harvested and washed in RT in buffer containing PBS with 1 mM EDTA and 2% FBS. The number of cells labeled with Spike-AF488 was quantified using flow cytometry.

Cellular thermal-shift assay (CETSA). CETSA was done based on the method of Jafari et al., 2014, with modifications for membrane proteins. Cells were transfected with Spike-Flag, and 24 h following transfection cells were treated with 20 µM imatinib for 3 h. Cells were non-enzymatically harvested and prepared as suspensions in PBS supplemented with protease inhibitors, with or without 20 µM imatinib. Cells were aliquoted into a series of PCR tubes, which were then subjected to a three mins heat shock (42–66 °C) for generating melt curves, followed by three mins cooling at 25 °C, and snap frozen in liquid nitrogen. Samples were thaw, NP-40 was added (1% v/v final), and the cells were lysed by three freeze–thaw cycles in liquid nitrogen. Separation of remaining soluble proteins from aggregates was done by centrifugation at 17,000 g for 20 min at 4 °C. The supernatants were analyzed by SDS-PAGE followed by Western blot analysis which displays the levels of thermally stable proteins.

Statistics and graphs. All statistical test and graphs were accomplished with the help of GraphPad Prism software. If not otherwise described all the experiments were conducted with three biological replicates. In most of the experiments each value is of three technical replicates. To perform statistical test, the standard deviation of the reference bar, set to 1.0, were calculated from all technical replicates. T-tests are two-tailed and statistical bars are standard deviations.
2. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).
3. Wang, C., Horby, P. W., Hayden, F. G. & Gao, G. F. A novel coronavirus outbreak of global health concern. Lancet 395, 470–473 (2020).
4. Gorbalsen, A. E. et al. The species severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, 536–544 (2020).
5. COVID-19 Map—Johns Hopkins Coronavirus Resource Center. Available at: https://coronavirus.jhu.edu/map.html. (Accessed: 20th December 2020).
6. WHO Director-General’s remarks at the media briefing on 11 February 2020. Available at: https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. (Accessed: 20th October 2020).
7. Hartenian, E. et al. The molecular virology of coronaviruses. J. Biol. Chem. 14, 2020.
8. Fung, T. S. & Liu, D. X. Human coronavirus: Host–pathogen interaction. Annu. Rev. Microbiol. 73, 529–557 (2019).
9. V’kovskii, P., Kraztzel, A., Steinner, S., Stalder, H. & Thié, V. Coronavirus biology and replication: Implications for SARS-CoV-2. Nat. Rev. Microbiol. https://doi.org/10.1038/s41579-020-00468-6 (2020).
10. Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell https://doi.org/10.1016/j.cell.2020.02.052 (2020).
11. Ou, X. et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 11, 1–12 (2020).
12. Ruan, Z. et al. SARS-CoV-2 and SARS-CoV: Virtual screening of potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12). J. Med. Virol. 93, 389–400 (2021).
13. Tang, T., Bidon, M., Jaimes, J. A., Whittaker, G. R. & Daniel, S. Coronavirus membrane fusion mechanism offers a potential target for antiviral development. Antivir. Res. 178, 104792 (2020).
14. Koch, J. et al. TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells. EMBO J. https://doi.org/10.15222/EMBI.2021.107821 (2021).
15. Bestle, D. et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci. Alliance 3, E972 (2020).
16. Dynast, J. et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob. Agents Chemother. 58, 4885–4893 (2014).
17. Coleman, C. M. et al. Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion. J. Virol. 90, 8924–8933 (2016).
18. Sisk, J. M., Friedman, M. B. & Machamer, C. E. Coronavirus S protein–induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. J. Gen. Virol. 99, 619–630 (2018).
19. Cagno, V., Magliocco, G., Tapparel, C. & Daali, Y. The tyrosine kinase inhibitor nilotinib inhibits SARS-CoV-2 in vitro. Basic Clin. Pharmacol. Toxicol. 128, 621–624 (2021).
20. Weston, S., Haupt, R., Logue, J., Matthews, K. & Friedman, M. FDA approved drugs with broad anti-coronavirus activity inhibit SARS-CoV-2 in vitro. bioRxiv https://doi.org/10.1101/2020.03.02.972935 (2020).
21. Li, Y. et al. Identification of candidate COVID-19 therapeutics using hPSC-derived lung organoids. Nature https://doi.org/10.1038/s41586-020-25884-2 (2020).
22. Kalmanti, L. et al. Safety and efficacy of imatinib in CML over a period of 10 years: Data from the randomized CML-study IV. Leukemia 29, 1123–1132 (2015).
23. Wong, S. & Witte, O. N. The BCR-ABL story: Bench to bedside and back. Annu. Rev. Immunol. 22, 247–306 (2004).
24. Blanke, C. D. et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J. Clin. Oncol. 26, 626–632 (2008).
25. Colicelli, J. ABL tyrosine kinases: Evolution of function, regulation, and specificity. Sci. Signal. 3, re6 (2010).
26. Khatri, A., Wang, J. & Pendergast, A. M. Multifunctional Abl kinases in health and disease. Annu. Rev. Immunol. 34, 9–16 (2016).
27. Harcourt, J. et al. Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient. bioRxiv (2020). https://doi.org/10.1101/2020.03.02.972935.
28. Sanders, D. W. et al. SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation. Elife 10 (2021).
29. Leroy, H. et al. Virus-mediated cell–cell fusion. Int. J. Mol. Sci. 21, 1–28 (2020).
30. Miller, K. E., Kim, Y., Huh, W.-K. & Park, H.-O. Bimolecular fluorescence complementation (BiFC) analysis: Advances and recent applications for genome-wide interaction studies. J. Mol. Biol. 427, 2039 (2019).
31. Xu, C. D., Ch 는iew, V. & Kerppola, T. K. Visualization of interactions among BZip and rel family proteins in living cells using bimolecular fluorescence complementation. Mol. Cell 9, 789–798 (2002).
32. Turk, V. et al. Cysteine cathepsins: From structure, function and regulation to new frontiers. Biochim. Biophys. Acta. Proteins Proteom. 1824, 68 (2012).
33. Molina, D. M. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science (80-) 341, 84–87 (2013).
34. Jafari, R. et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat. Protoc. 9, 2100–2122 (2014).
35. Puelles, V. G. et al. Multispecie and renal tropism of SARS-CoV-2. N. Engl. J. Med. 383, 590–592 (2020).
36. Ondruschka, B. et al. Multispecie tropism of SARS-CoV-2 lineage B.1.1.7. Int. J. Legal Med. https://doi.org/10.1007/s00414-020-1026-1 (2021).
37. Awana, H. A. et al. SARS-CoV-2 and the brain: What do we know about the causality of cognitive COVID?. J. Clin. Med. 10, 3441 (2021).
38. Ou, T. et al. Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2. PLoS Pathog. 17, e1009212 (2021).
39. Mulgaonkar, N. et al. Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19. bioRxiv (2020). https://doi.org/10.1101/2020.06.18.158196.
40. Nejat, R. & Sadr, A. S. Are losartan and imatinib effective against SARS-CoV2 pathogens? A pathophysiology-based in silico study. Silico Pharmacol. 9 (2021).
41. Lau, E. Y. et al. Discovery of small-molecule inhibitors of SARS-CoV-2 proteins using a computational and experimental pipeline. Front. Mol. Biosci. 8 (2021).
42. Nabi, F. et al. Computational studies on phylogeny and drug designing using molecular simulations for COVID-19. J. Biomol. Struct. Dyn. https://doi.org/10.1080/07391102.2021.1947895 (2021).
43. Harmon, B., Campbell, N. & Ratner, L. Role of Abl kinase and the wave2 signaling complex in HIV-1 entry at a post-hemifusion step. PLoS Pathog. 6, 1000956 (2010).
44. Min, S. et al. Abl tyrosine kinase regulates hepatitis C virus entry. Front. Microbiol. 8 (2017).
45. Hrinicusa, E. R. et al. Avian influenza viruses inhibit the major cellular signalling integrator c-Ab. Cell. Microbiol. 16, 1854–1874 (2014).
46. Coyne, C. B. & Bergelson, J. M. Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell 124, 119–131 (2006).
Acknowledgements
We thank Ori Avinoam, Suman Khan and Nina Reuven for helpful discussions. We thank Assaf Biran for preparation of Fos-YFPc and Jun-YFPn plasmids. This study was supported by Miel de Botton and by a Grant from State of Israel Ministry of Science and Technology.

Author contributions
R.S. and Y.S. designed the study and respective experiments, analyzed the data and prepared the manuscript; R.S. performed experiments, prepared the figures and performed statistical tests; J.A. performed experiments and advised experimental settings; Y.Y.-R., S.M., B.P. and N.P. performed all BSL3 experiments with SARS-CoV-2; Z.S. advised experimental settings; D.S. performed experiments and advised experimental settings; All authors reviewed and edited the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-09664-1.

Correspondence and requests for materials should be addressed to Y.S.

Reprints and permissions information
Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022